A Study of Camrelizumab Combined with Docetaxel and Carboplatin as Neoadjuvant Treatment in Locally Advanced ESCC

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 15 Dec 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

24 Oct 2023 Results (n=40) assessing the clinical efficacy and safety of neoadjuvant camrelizumab combined with docetaxel and carboplatin in locally advanced oesophageal squamous cell carcinoma, presented at the 48th European Society for Medical Oncology Congress.
13 Sep 2022 Results (n=30; From Oct 2019 to Feb 2022) assessing the efficacy and adverse events (AEs) of camrelizumab plus docetaxel and carboplatin as neoadjuvant treatment in locally advanced esophageal squamous cell carcinoma, presented at the 47th European Society for Medical Oncology Congress.
04 Aug 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com